Target intelligence / Profile preview

Mumps virus fusion glycoprotein F (F protein)

Target
F protein
Molecular classification
Viral fusion glycoprotein, Class I fusion protein, Envelope protein
01

Overview

The Mumps virus fusion glycoprotein F is a surface envelope protein of the mumps virus (family Paramyxoviridae, genus Rubulavirus)[1][4]. It is produced as an inactive precursor (F0) and activated by host cell proteases (such as furin) by cleavage into two subunits, F1 and F2, which are linked by disulfide bonds[4]. Structural studies show it forms a trimeric complex at the virus surface with two heptad repeat domains, assembling into a six-helix bundle upon triggering by receptor engagement of the hemagglutinin-neuraminidase (HN) protein[1][7][2]. This conformational change exposes a highly hydrophobic fusion peptide that inserts into the host cell membrane and mediates membrane merger at neutral pH[4]. The F protein is critical for viral entry, spread, and is a target for neutralizing antibodies induced by vaccination[9]. Variability in the F protein sequence (such as cleavage site or fusogenic domains) can affect virulence, cell tropism, and immune recognition[5][9]. Its structure and function are homologous to fusion proteins in other paramyxoviruses and are subject to ongoing vaccine research[2][8].

Other names
Mumps virus F proteinFusion proteinFusion glycoprotein F
02

Mechanism of action

Prevention of fusion and viral entry through neutralizing antibodies generated by vaccination Experimental fusion inhibitors could block conformational changes required for membrane fusion

03

Biological functions

Viral entry via membrane fusionCell-to-cell fusion (syncytium formation)Virulence determinantInduces host immune response
04

Disease associations

Infection (mumps and its complications: parotitis, neurological disease, orchitis)Viral pathogenesis and host cell tropism
05

Safety considerations

Antigenic variation can reduce efficacy of vaccines (escape variants)Inducing immune responses against F protein may risk off-target effects if cross-reactivity with human proteins occurs, though not a major concern seen with current mumps vaccines
06

Interacting drugs

Mumps vaccine
07

Biomarkers

Anti-F protein antibody titers for post-vaccination or infection statusGenetic variants in F protein sequence (fusogenicity, virulence)

Beyond the preview

Go deeper on Mumps virus fusion glycoprotein F (F protein).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mumps virus fusion glycoprotein F (F protein).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call